Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0AWHCA
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CN107735105B ADC-3
|
|||||
| Synonyms |
CN107735105B_ADC-3
Click to Show/Hide
|
|||||
| Organization |
Seagen Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 2 Indication(s)
Acute myeloid leukemia [ICD11:2A60]
Investigative
Non-Hodgkin lymphoma [ICD11:2B33]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Anti-SLAMF6 mAb
|
Antibody Info | ||||
| Antigen Name |
SLAM family member 6 (SLAMF6)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
CN107735105B ADC-3 linker
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 50.00% (Day 25) | Positive SLAMF6 expression (SLAMF6+++/++) | ||
| Method Description |
Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 0.025 mg/kg ADC.
Click to Show/Hide
|
||||
| In Vivo Model | Raji CDX model | ||||
| In Vitro Model | EBV-related Burkitt lymphoma | Raji cells | CVCL_0511 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 61.10% (Day 31) | Positive SLAMF6 expression (SLAMF6+++/++) | ||
| Method Description |
Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 0.025 mg/kg ADC.
Click to Show/Hide
|
||||
| In Vivo Model | WSU?DLCL2 CDX model | ||||
| In Vitro Model | Diffuse large B-cell lymphoma | WSU-DLCL2 cells | CVCL_1902 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 76.70% (Day 31) | Positive SLAMF6 expression (SLAMF6+++/++) | ||
| Method Description |
Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 0.05 mg/kg ADC.
Click to Show/Hide
|
||||
| In Vivo Model | WSU?DLCL2 CDX model | ||||
| In Vitro Model | Diffuse large B-cell lymphoma | WSU-DLCL2 cells | CVCL_1902 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 90.00% (Day 45) | Positive SLAMF6 expression (SLAMF6+++/++) | ||
| Method Description |
Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 0.037mg/kg ADC.
Click to Show/Hide
|
||||
| In Vivo Model | NHT-34 CDX model | ||||
| In Vitro Model | Acute myeloid leukemia | HNT-34 cells | CVCL_2071 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 90.10% (Day 45) | Positive SLAMF6 expression (SLAMF6+++/++) | ||
| Method Description |
Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 0.111 mg/kg ADC.
Click to Show/Hide
|
||||
| In Vivo Model | NHT-34 CDX model | ||||
| In Vitro Model | Acute myeloid leukemia | HNT-34 cells | CVCL_2071 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 94.40% (Day 31) | Positive SLAMF6 expression (SLAMF6+++/++) | ||
| Method Description |
Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 0.1 mg/kg ADC.
Click to Show/Hide
|
||||
| In Vivo Model | WSU?DLCL2 CDX model | ||||
| In Vitro Model | Diffuse large B-cell lymphoma | WSU-DLCL2 cells | CVCL_1902 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 25) | Positive SLAMF6 expression (SLAMF6+++/++) | ||
| Method Description |
Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 0.05 mg/kg ADC.
Click to Show/Hide
|
||||
| In Vivo Model | Raji CDX model | ||||
| In Vitro Model | EBV-related Burkitt lymphoma | Raji cells | CVCL_0511 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 25) | Positive SLAMF6 expression (SLAMF6+++/++) | ||
| Method Description |
Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 0.1 mg/kg ADC.
Click to Show/Hide
|
||||
| In Vivo Model | Raji CDX model | ||||
| In Vitro Model | EBV-related Burkitt lymphoma | Raji cells | CVCL_0511 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 45) | Positive SLAMF6 expression (SLAMF6+++/++) | ||
| Method Description |
Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 0.333 mg/kg ADC.
Click to Show/Hide
|
||||
| In Vivo Model | NHT-34 CDX model | ||||
| In Vitro Model | Acute myeloid leukemia | HNT-34 cells | CVCL_2071 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.50 ng/mL | Positive SLAMF6 expression (SLAMF6+++/++) | ||
| Method Description |
The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.
Click to Show/Hide
|
||||
| In Vitro Model | Acute myeloid leukemia | HNT-34 cells | CVCL_2071 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.80 ng/mL | Positive SLAMF6 expression (SLAMF6+++/++) | ||
| Method Description |
The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.
Click to Show/Hide
|
||||
| In Vitro Model | Burkitt lymphoma | Ramos cells | CVCL_0597 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.90 ng/mL | Positive SLAMF6 expression (SLAMF6+++/++) | ||
| Method Description |
The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.
Click to Show/Hide
|
||||
| In Vitro Model | Burkitt lymphoma | CA46 cells | CVCL_1101 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.00 ng/mL | Positive SLAMF6 expression (SLAMF6+++/++) | ||
| Method Description |
The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.
Click to Show/Hide
|
||||
| In Vitro Model | Plasma cell myeloma | MM1.R cells | CVCL_8794 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.00 ng/mL | Positive SLAMF6 expression (SLAMF6+++/++) | ||
| Method Description |
The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.
Click to Show/Hide
|
||||
| In Vitro Model | Plasma cell myeloma | MM1.S cells | CVCL_8792 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 2.00 ng/mL | Positive SLAMF6 expression (SLAMF6+++/++) | ||
| Method Description |
The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.
Click to Show/Hide
|
||||
| In Vitro Model | Erythroleukemia | HEL 92.1.7 cells | CVCL_2481 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 8.00 ng/mL | Positive SLAMF6 expression (SLAMF6+++/++) | ||
| Method Description |
The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.
Click to Show/Hide
|
||||
| In Vitro Model | Plasma cell myeloma | U-266 cells | CVCL_0015 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.